INSM

Insmed Incorporated NASDAQ

Healthcare ·Biotechnology ·US · insmed.com

$140.01

Mkt Cap $30.2B

52w Low $63.81 51.2% of range 52w High $212.75

50d MA $147.31 200d MA $155.30

P/E (TTM) -20.8x

EV/EBITDA -32.0x

P/B 38.5x

Debt/Equity 1.0x

ROE -172.8%

P/FCF -38.4x

RSI (14) —

ATR (14) —

Beta 1.10

50d MA $147.31

200d MA $155.30

Avg Volume 2.3M

About

Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatme…

Recent Earnings

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	1M%	Guide ▲★
Feb 19, 2026	AMC	-1.07	-1.54	-43.9%	161.00	-1.6%	+2.4%	-1.2%	-1.5%	-7.7%	-6.8%	-10.6%	—
Oct 30, 2025	AMC	-1.33	-1.75	-31.6%	194.22	+0.2%	-2.4%	-4.1%	-5.9%	-3.8%	-4.4%	+8.9%	—
Aug 7, 2025	AMC	-1.30	-1.70	-30.8%	109.30	-0.6%	+0.2%	+3.3%	+11.6%	+12.4%	+16.9%	+34.2%	—
May 8, 2025	AMC	-1.34	-1.42	-6.0%	65.63	+0.0%	-0.8%	+3.2%	+0.1%	-0.0%	+2.4%	+7.7%	—
Feb 20, 2025	AMC	-1.17	-1.32	-12.8%	83.61	+1.0%	-3.0%	-4.3%	-7.3%	-6.6%	-5.5%	-5.1%	—
Oct 31, 2024	AMC	-1.20	-1.27	-5.8%	67.28	+0.7%	+1.5%	+1.2%	+3.0%	+8.3%	+6.6%	+7.6%	—
Aug 8, 2024	AMC	-1.24	-1.94	-56.5%	71.81	+1.4%	+3.0%	+3.2%	+6.4%	+4.3%	+3.2%	+0.0%	—
May 9, 2024	AMC	-1.24	-1.06	+14.5%	26.38	+0.7%	-1.6%	-2.1%	-3.5%	-5.5%	-4.9%	+127.1%	—
Feb 22, 2024	AMC	-1.13	-1.28	-13.3%	27.15	+1.0%	+0.5%	+5.9%	+7.7%	+3.2%	+2.1%	-0.6%	—
Oct 26, 2023	AMC	-1.06	-1.10	-3.8%	25.55	+1.8%	-6.5%	-6.8%	-1.9%	-2.2%	-2.1%	-6.3%	—
Aug 3, 2023	AMC	-1.10	-1.78	-61.8%	22.15	+0.0%	-0.7%	-1.3%	-0.5%	-2.8%	+2.6%	+19.1%	—
May 4, 2023	AMC	-1.08	-1.17	-8.3%	19.56	+0.7%	-0.8%	-3.4%	-3.2%	-2.0%	-3.1%	-0.5%	—

Recent Analyst Ratings

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
Apr 17	Roth Capital	Maintains	Buy → Buy	—	$142.79	$144.25	+1.0%	+1.2%	+0.0%	-1.3%	+1.2%	+0.7%
Apr 14	RBC Capital	Maintains	Outperform → Outperform	—	$151.14	$152.21	+0.7%	+1.5%	-2.9%	-5.5%	-4.4%	-5.5%
Apr 1	Barclays	Maintains	Overweight → Overweight	—	$163.52	$164.49	+0.6%	+0.8%	-0.7%	+0.2%	-0.3%	-2.0%
Mar 30	Morgan Stanley	Upgrade	Equal Weight → Overweight	—	$145.30	$150.98	+3.9%	+5.5%	+12.5%	+13.5%	+11.8%	+12.7%
Mar 26	HC Wainwright & Co.	Maintains	Buy → Buy	—	$148.31	$148.45	+0.1%	-0.5%	-2.0%	+3.4%	+10.3%	+11.2%
Mar 25	Mizuho	Maintains	Outperform → Outperform	—	$139.14	$140.00	+0.6%	+6.6%	+6.1%	+4.4%	+10.2%	+17.5%
Mar 24	Leerink Partners	Maintains	Outperform → Outperform	—	$143.98	$144.42	+0.3%	-3.4%	+3.0%	+2.5%	+0.9%	+6.5%
Mar 24	Stifel	Maintains	Buy → Buy	—	$143.98	$144.42	+0.3%	-3.4%	+3.0%	+2.5%	+0.9%	+6.5%
Mar 24	BofA Securities	Maintains	Buy → Buy	—	$143.98	$144.42	+0.3%	-3.4%	+3.0%	+2.5%	+0.9%	+6.5%
Mar 24	Wells Fargo	Maintains	Overweight → Overweight	—	$143.98	$144.42	+0.3%	-3.4%	+3.0%	+2.5%	+0.9%	+6.5%
Mar 23	Wells Fargo	Maintains	Overweight → Overweight	—	$136.00	$147.12	+8.2%	+5.9%	+2.3%	+9.1%	+8.5%	+6.8%
Feb 24	Mizuho	Maintains	Outperform → Outperform	—	$159.03	$156.00	-1.9%	-0.3%	-6.6%	-5.7%	-6.1%	-8.0%
Feb 23	HC Wainwright & Co.	Maintains	Buy → Buy	—	$164.91	$163.60	-0.8%	-3.6%	-3.8%	-9.9%	-9.0%	-9.4%
Feb 20	Wells Fargo	Maintains	Overweight → Overweight	—	$161.00	$158.39	-1.6%	+2.4%	-1.2%	-1.5%	-7.7%	-6.8%
Jan 30	Morgan Stanley	Maintains	Equal Weight → Equal Weight	—	$157.82	$157.19	-0.4%	-0.6%	-2.4%	-0.4%	-3.4%	-4.3%
Jan 21	RBC Capital	Maintains	Outperform → Outperform	—	$163.51	$163.00	-0.3%	-4.4%	-1.9%	-4.5%	-2.3%	-0.5%
Jan 6	UBS	Maintains	Buy → Buy	—	$175.20	$173.33	-1.1%	-0.1%	+0.5%	-2.8%	+0.4%	-4.3%
Dec 18	HC Wainwright & Co.	Maintains	Buy → Buy	—	$198.46	$167.75	-15.5%	-16.1%	-11.9%	-11.4%	-10.9%	-10.6%
Dec 18	Guggenheim	Maintains	Buy → Buy	—	$198.46	$167.75	-15.5%	-16.1%	-11.9%	-11.4%	-10.9%	-10.6%
Dec 18	Goldman Sachs	Maintains	Buy → Buy	—	$198.46	$167.75	-15.5%	-16.1%	-11.9%	-11.4%	-10.9%	-10.6%
Dec 18	RBC Capital	Maintains	Outperform → Outperform	—	$198.46	$167.75	-15.5%	-16.1%	-11.9%	-11.4%	-10.9%	-10.6%
Dec 18	TD Cowen	Maintains	Buy → Buy	—	$198.46	$167.75	-15.5%	-16.1%	-11.9%	-11.4%	-10.9%	-10.6%
Dec 16	Wells Fargo	Maintains	Overweight → Overweight	—	$196.92	$195.39	-0.8%	+1.9%	+0.8%	-15.4%	-11.2%	-10.7%
Dec 16	Cantor Fitzgerald	Maintains	Overweight → Overweight	—	$196.92	$195.39	-0.8%	+1.9%	+0.8%	-15.4%	-11.2%	-10.7%
Dec 15	Goldman Sachs	Maintains	Buy → Buy	—	$197.01	$197.23	+0.1%	-0.0%	+1.9%	+0.7%	-15.5%	-11.3%
Dec 11	TD Cowen	Maintains	Buy → Buy	—	$189.85	$190.24	+0.2%	+2.8%	+3.8%	+3.7%	+5.7%	+4.5%
Dec 1	Mizuho	Maintains	Outperform → Outperform	—	$207.77	$206.80	-0.5%	+1.8%	-0.6%	-0.5%	-1.3%	-1.8%
Nov 20	TD Cowen	Maintains	Buy → Buy	—	$203.56	$204.35	+0.4%	-1.9%	-2.4%	+1.7%	+2.7%	+0.5%
Oct 31	UBS	Maintains	Buy → Buy	—	$194.22	$194.57	+0.2%	-2.4%	-4.1%	-5.9%	-3.8%	-4.4%
Oct 31	Goldman Sachs	Maintains	Buy → Buy	—	$194.22	$194.57	+0.2%	-2.4%	-4.1%	-5.9%	-3.8%	-4.4%
Oct 31	RBC Capital	Maintains	Outperform → Outperform	—	$194.22	$194.57	+0.2%	-2.4%	-4.1%	-5.9%	-3.8%	-4.4%
Oct 31	Wells Fargo	Maintains	Overweight → Overweight	—	$194.22	$194.57	+0.2%	-2.4%	-4.1%	-5.9%	-3.8%	-4.4%
Oct 27	BofA Securities	Maintains	Buy → Buy	—	$159.66	$162.05	+1.5%	+2.7%	+3.5%	+4.6%	+21.6%	+18.8%
Oct 14	UBS	Maintains	Buy → Buy	—	$163.94	$163.99	+0.0%	-1.6%	-0.2%	-0.5%	+1.1%	+2.4%
Oct 3	Goldman Sachs	Maintains	Buy → Buy	—	$152.80	$153.00	+0.1%	+2.9%	+3.6%	+6.2%	+5.9%	+7.6%
Oct 2	TD Cowen	Maintains	Buy → Buy	—	$147.28	$148.70	+1.0%	+3.7%	+6.7%	+7.5%	+10.2%	+9.9%
Sep 8	Guggenheim	Maintains	Buy → Buy	—	$145.10	$144.50	-0.4%	+1.1%	+1.4%	+0.6%	+0.5%	+0.6%
Sep 3	Wells Fargo	Maintains	Overweight → Overweight	—	$145.30	$145.00	-0.2%	-1.2%	-1.9%	-0.1%	+0.9%	+1.3%
Aug 21	Morgan Stanley	Maintains	Equal Weight → Equal Weight	—	$129.45	$129.80	+0.3%	+2.4%	+1.9%	-0.9%	+2.1%	+3.9%
Aug 20	JP Morgan	Maintains	Overweight → Overweight	—	$127.21	$127.43	+0.2%	+1.8%	+4.2%	+3.7%	+0.9%	+3.9%
Aug 14	Truist	Maintains	Buy → Buy	—	$122.87	$125.50	+2.1%	+4.0%	+4.0%	+3.6%	+3.5%	+5.4%
Aug 14	Stifel	Maintains	Buy → Buy	—	$122.87	$125.50	+2.1%	+4.0%	+4.0%	+3.6%	+3.5%	+5.4%
Aug 13	RBC Capital	Maintains	Outperform → Outperform	—	$122.00	$121.16	-0.7%	+0.7%	+4.7%	+4.8%	+4.3%	+4.3%
Aug 13	Goldman Sachs	Maintains	Buy → Buy	—	$122.00	$121.16	-0.7%	+0.7%	+4.7%	+4.8%	+4.3%	+4.3%
Aug 13	Jefferies	Maintains	Buy → Buy	—	$122.00	$121.16	-0.7%	+0.7%	+4.7%	+4.8%	+4.3%	+4.3%
Aug 13	Morgan Stanley	Downgrade	Overweight → Equal Weight	—	$122.00	$121.16	-0.7%	+0.7%	+4.7%	+4.8%	+4.3%	+4.3%
Aug 13	HC Wainwright & Co.	Maintains	Buy → Buy	—	$122.00	$121.16	-0.7%	+0.7%	+4.7%	+4.8%	+4.3%	+4.3%
Aug 13	Mizuho	Maintains	Outperform → Outperform	—	$122.00	$121.16	-0.7%	+0.7%	+4.7%	+4.8%	+4.3%	+4.3%
Aug 13	UBS	Maintains	Buy → Buy	—	$122.00	$121.16	-0.7%	+0.7%	+4.7%	+4.8%	+4.3%	+4.3%
Aug 12	Wells Fargo	Maintains	Overweight → Overweight	—	$112.89	$112.89	+0.0%	+8.1%	+8.8%	+13.2%	+13.2%	+12.7%

Recent Filings

8-K · 8.01 !! High

Unknown — 8-K 8.01: Material Event / Announcement

Brensocatib failed its primary efficacy endpoint as placebo outperformed both drug doses, likely triggering stock decline and raising questions about the treatment's viability in hidradenitis suppurativa.

Apr 7

8-K · 8.01 !! High

Unknown — 8-K 8.01: Material Event / Announcement

INSM's ENCORE study showed positive results for its tuberculosis treatment, potentially supporting future regulatory approval and commercialization prospects that investors should monitor for revenue growth.

Mar 23

8-K · 5.02 !!! Very High

Insmed, Inc. -- 8-K 5.02: Executive Change

Insmed's Chief Executive Officer McGirr will not seek re-election, signaling potential leadership transition that could impact strategic direction and investor confidence in the company's pipeline execution.

Feb 19

Data updated apr 25, 2026 3:46pm · Source: massive.com